indacaterol

indacaterol

(in-da-kat-e-role) ,

Arcapta Neohaler

(trade name),

Onbrez Breezhaler

(trade name)

Classification

Therapeutic: bronchodilators
Pharmacologic: adrenergics
Pregnancy Category: C

Indications

Long-term maintenance treatment of airflow obstruction associated with chronic obstructive pulmonary disease (COPD).

Action

Produces accumulation of cyclic adenosine monophosphate (cAMP) at beta2-adrenergic receptors. Relatively specific for pulmonary receptors.
Acts as a long-acting beta-agonist (LABA).

Therapeutic effects

Bronchodilation, with improvement in symptoms of COPD.

Pharmacokinetics

Absorption: Some systemic absorption from lungs and GI tract (43–45%).
Distribution: Extensively distributed.
Metabolism and Excretion: 54% excreted unchanged in feces; absorbed drug is mostly metabolized; 23% excreted in feces as metabolites.
Half-life: 45.5–126 hr.

Time/action profile (blood levels)

ROUTEONSETPEAKDURATION
Inhalnunknown15 min24 hr†
† Bronchodilation.

Contraindications/Precautions

Contraindicated in: HypersensitivityAcutely deteriorating COPD or acute respiratory symptoms;Asthma.
Use Cautiously in: Obstetric: Use during pregnancy only if potential benefit justifies potential fetal risks; may interfere with uterine contractility during labor; Pediatric: Safety and effectiveness not established.
Exercise Extreme Caution in: Concurrent use of MAO inhibitors, tricyclic antidepressants or drugs that prolong the QTc interval (↑ risk of adverse cardiovascular reactions).

Adverse Reactions/Side Effects

Central nervous system

  • headache

Ear, Eye, Nose, Throat

  • nasopharyngitis
  • oropharyngeal pain

Respiratory

  • paradoxical bronchospasm (life-threatening)
  • cough

Gastrointestinal

  • nausea

Miscellaneous

  • allergic reactions (life-threatening)

Interactions

Drug-Drug interaction

↑ risk of serious adverse cardiovascular effects with MAO inhibitors, tricyclic antidepressants, drugs that prolong the QTc interval ; use with extreme caution.Effectiveness may be ↓ by beta-blockers; use cautiously and only when necessary.Concurrent use with other adrenergics may ↑ adrenergic adverse reactions (↑ heart rate, BP, jitteriness).↑ risk of hypokalemia or ECG changes with xanthine derivatives, corticosteroids, diuretics, or non-potassium sparing diuretics.Use with caffeine-containing herbs (cola nut, guarana, mate, tea, coffee) ↑ stimulant effect.

Route/Dosage

Inhalation (Adults) 75 mcg once daily.

Availability

Capsules for inhalation: 75 mcg

Nursing implications

Nursing assessment

  • Assess respiratory status (rate, breath sounds, degree of dyspnea, pulse) before administration and at peak of medication. Consult health care professional about alternative medication if severe bronchospasm is present; onset of action is too slow for patients in acute distress. If paradoxical bronchospasm (wheezing) occurs, withhold medication and notify health care professional immediately.
  • Monitor for signs and symptoms of allergic reactions (difficulties in breathing or swallowing, swelling of tongue, lips and face, urticaria, skin rash). Discontinue therapy if symptoms occur.
  • Lab Test Considerations: May cause transient hypokalemia and hyperglycemia.

Potential Nursing Diagnoses

Ineffective airway clearance (Indications)
Risk for activity intolerance (Indications)

Implementation

  • Inhalation: Pull cap off Neohaler. Open inhaler by holding the base and tilting the mouthpiece. Tear perforation to separate one blister from blister card; peal away protective back to expose foil. With dry hands, push capsule through foil to remove. Insert capsule into capsule chamber; do not swallow capsule or place directly into mouthpiece. Close inhaler until it clicks. Press both buttons fully 1 time; click is heard as capsule is pierced; do not press piercing buttons more than 1 time. Release buttons fully. Breathe out; do not blow into mouthpiece. Close lips around mouthpiece; hold inhaler with buttons left and right (not up and down). Breathe in rapidly and steadily, as deep as possible, a whirring noise is heard. Continue to hold breath as long as possible while removing inhaler from mouth. Open inhaler, if powder remains in capsule, close inhaler and inhale again. Usually requires 1–2 breaths. Remove capsule.

Patient/Family Teaching

  • Instruct patient in the correct use of capsules and Neohaler. Advise patient not to discontinue without consulting health care professional; symptoms may recur.
  • Inform patient that indacaterol is not a bronchodilator and should not be used for treating sudden breathing problems.
  • Advise patient to notify health care professional if signs and symptoms of allergic reaction, worsening symptoms; decreasing effectiveness of inhaled, short-acting beta2-agonists; need for more inhalations than usual of inhaled, short-acting beta2-agonists; or significant decrease in lung function occur.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to avoid concurrent use of Rx, OTC, and herbal products without consulting health care professional.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breast feeding.

Evaluation/Desired Outcomes

  • Decrease in the number of flare-ups or the worsening of COPD symptoms (exacerbations).
References in periodicals archive ?
2]-adrenergic agonists, such as indacaterol, one of the active ingredients in Utibron Neohaler, increase the risk of asthma-related death.
2] agonists--the ultra-LABAs--and include indacaterol, carmoterol, vilanterol and olodaterol.
These include Onbrez Inhalation Capsules 150 mcg (indacaterol maleate), which were launched in Japan on September 20, 2011, and, if approved, the investigational drugs NVA237 (glycopyrronium bromide) and QVA149 (fixed-dose combination of indacaterol maleate and glycopyrronium bromide), both of which are currently in Phase III development.
Patients with chronic obstructive pulmonary disease have been found to breathe easier after taking indacaterol, also known as Onbrez Breezhaler.
The collaboration was expanded in August 2006 to include the joint development and commercialization of a fixed-dose combination of indacaterol and mometasone furoate.
The indacaterol data presented at ATS show that bronchodilation on a once-daily basis may be an important addition to the current therapeutic armamentarium in COPD.
Five studies in the program - comprising 10 studies in total with more than 7,000 patients across 42 countries - all met their primary endpoints and showed that QVA149 significantly improved lung function compared to other COPD therapies like tiotropium, indacaterol, salmeterol/fluticasone and glycopyrronium bromide.
Tenders are invited for Indacaterol 150Mcg In Phial Of 30 Caps With Brezahaler Device Onbrez
2]-agonist indacaterol outperformed salmeterol and placebo in a double-blind, randomized clinical trial involving 998 patients with moderate to severe COPD.
arformoterol (for nebuliser use), and carmoterol, indacaterol, and new long-acting anticholinergics (10)
Schering-Plough's once daily inhaled corticosteroid mometasone, the active ingredient in ASMANEX(R) and Novartis' once daily beta2-agonist indacaterol (QAB149) will be combined in a single inhalation device.